Literature DB >> 16622643

[What is practically important when carrying out a chemotherapy?].

M Schenck1, T Jäger.   

Abstract

The patient stands at the center of a chemotherapy. The aim of the curative or palliative treatment is not only the death of the tumor cells, but also the maintenance or improvement of the patient's physical condition, especially the improvement of quality of life. Before starting the therapy, it is necessary to determine, for example, the patient's general condition and motivation, and to carry out a consultation. Examinations, for example, blood tests, audiograms, renal function and lung function should also be made. Thus, the patient's tolerance for even the most onerous chemotherapy can be investigated and patients can be individually prepared for the treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16622643     DOI： 10.1007/s00120-006-1045-3

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  15 in total

1.  Multinational Association of Supportive Cancer Care (MASCC).

Authors:  Fausto Roila
Journal:  Support Care Cancer       Date:  2003-04       Impact factor: 3.603

2.  Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.

Authors:  Arti Hurria; Anju Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Jane Howard; Clifford Hudis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Optimising antiemetic therapy: what are the problems and how can they be overcome?

Authors:  Matti Aapro
Journal:  Curr Med Res Opin       Date:  2005-06       Impact factor: 2.580

Review 4.  [Systemic cytostatic chemotherapy].

Authors:  H Sauer
Journal:  Internist (Berl)       Date:  1998-11       Impact factor: 0.743

5.  Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.

Authors:  Olivier Mir; Jérôme Alexandre; Stanislas Ropert; Delphine Amsellem-Ouazana; Thierry Flam; Philippe Beuzeboc; Marc Zerbib; Bernard Debré; Loïc Guillevin; François Goldwasser
Journal:  Anticancer Drugs       Date:  2005-10       Impact factor: 2.248

6.  [Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration].

Authors:  P R Grahmann; M Brauer; L Hüter; H Sayer; R Neumann; R K Braun
Journal:  Pneumologie       Date:  2005-11

Review 7.  Utilization of comprehensive geriatric assessment in cancer patients.

Authors:  Cheryl Chia-Hui Chen; Amy L Kenefick; Siew Tzuh Tang; Ruth McCorkle
Journal:  Crit Rev Oncol Hematol       Date:  2004-01       Impact factor: 6.312

8.  Relationship between cisplatin administration and the development of ototoxicity.

Authors:  Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; Nico van Zandwijk; Jan H M Schellens
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

9.  Separate mechanisms for procarbazine spermatotoxicity and anticancer activity.

Authors:  M G Horstman; G G Meadows; G S Yost
Journal:  Cancer Res       Date:  1987-03-15       Impact factor: 12.701

10.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506
View more
  3 in total

1.  [How should urologists perform implantation of subcutaneous central venous port systems? A single center experience of 347 cases].

Authors:  M Schenck; W Michels-Oswald; S Tschirdewahn; H Rübben; F Vom Dorp; A Rose; A Panic; C Niedworok; R Rossi
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

2.  Central venous port implantations via the cephalic vein applying an intravasal electrographic control of the catheter tip position: a single-center experience of 316 cases.

Authors:  Marcus Schenck; Tim Schneider; Herbert Rübben; Andreas Eisenhardt
Journal:  World J Urol       Date:  2011-08-28       Impact factor: 4.226

3.  [Urogenital symptoms and possibilities for urological intervention in the palliative care situation].

Authors:  T Jäger; M Schenck
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.